Ligand Pharmaceuticals Incorporated

NASDAQ
LGND
Promotion
Rentabilité pendant six mois: -4.53%
Rendement des dividendes: 0%
Secteur: Healthcare

112.5 $

0 $ 0%
96.67 $
129.9 $

Min./max. pendant un an

Calendrier de promotion Ligand Pharmaceuticals Incorporated

Calendrier prolongé Calendrier simple
Financial Markets by TradingView
Ajouter la comparaison
Ajouter la piste
Ajouter au portefeuille
Ajouter une notification des prix

Les principaux paramètres

Devise
usd
Div
0
Dividende AO
0.456
Industrie
Biotechnology
Isin
US53220K5048
La monnaie du rapport
usd
Secteur
Health Care
Site web
Système
Temps d'introduction en bourse
1992-11-18
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 11.57 1
P/BV 2.33 6
P/E 24.35 6
Efficacité
Nom Signification Grade
ROA -0.4664 0
ROE -0.5266 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement des dividendes 0 0
DSI 0.5 5
La croissance moyenne des dividendes -1011.4 0
Devoir
Nom Signification Grade
Debt/EBITDA 0.1655 10
Debt/Ratio 0.0075 10
Debt/Equity 0.1341 10
Pouls de croissance
Nom Signification Grade
Revenus, milliards, % -10.34 0
Ebitda, % 34.19 5
EPS, % 24.27 4
En savoir plus

Prix

Prix Min. Max. Changement Changements dans l'industrie Changements dans l'index
Hier 112.5 $ 0 $ 0 $ 0 % 0 % 0 %
Semaine 113.42 $ 0 $ 0 $ -0.8111 % 0 % 0 %
Mois 101.6 $ 0 $ 0 $ +10.73 % 0 % 0 %
3 mois 104.27 $ 100.19 $ 115.39 $ +7.89 % 0 % 0 %
Six mois 117.84 $ 96.67 $ 122.23 $ -4.53 % 0 % 0 %
Année 106.54 $ 96.67 $ 129.9 $ +5.59 % 0 % 0 %
3 ans 60.2 $ 48.1 $ 129.9 $ +86.88 % 0 % 0 %
5 ans 117.93 $ 48.1 $ 215.83 $ -4.6 % 0 % 0 %
10 ans 48.1 $ 48.1 $ 274.49 $ +233.91 % 0 % 0 %
Année à ce jour 107.92 $ 96.67 $ 122.23 $ +4.24 % 0 % 0 %

Propriétaires de base

Contenu dans ETF

ETF
Partager, %
Rentabilité pour l'année, %
Commission, %
Syntax Stratified SmallCap ETF 0.3841 -41.87 0.40
IndexIQ ETF Trust IQ U.S. Small Cap ETF 0.25 54.74 0.35
Future Tech ETF 0.1841 479.5 0.35
Principal Healthcare Innovators ETF 0.1841 -3.92 0.35
iShares Morningstar Small-Cap Growth ETF 0.04601 557.86 0.06
iShares Morningstar Small-Cap ETF 0.0404 299.3 0.25
iShares Morningstar Small-Cap Value ETF 0.03432 175.97 0.06
0.16217.370.26

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


La gestion de l'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Mr. Matthew E. Korenberg President & COO 831.77k 1975 (50 années)
Mr. Octavio Espinoza Chief Financial Officer 613.59k 1971 (54 années)
Mr. Andrew T. Reardon J.D. Chief Legal Officer & Secretary 614.87k 1975 (50 années)
Mr. Todd Pettingill Director of Corporate Development N/A
Dr. Keith Marschke Senior Vice President of Biology & Scientific Affairs N/A
Dr. Vincent D. Antle Senior Vice President of Technical Operations & QA - Capitsol N/A 1969 (56 années)
Mr. Paul J. Hadden Senior Vice President of Investments & Business Development N/A
Mr. Patrick Lucy Senior VP & CBO Protein Expression Business N/A
Mr. Todd C. Davis Ph.D. CEO & Director 1961 (64 années)
Michael Jeong Head of Investor Relations

Informations sur l'entreprise

Adresse: United States, San Diego. CA, 3911 Sorrento Valley Boulevard - Ouvert sur google cards, Cartes yandex ouvertes
Site web: https://www.ligand.com

À propos de l'entreprise Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego, California.